Organigram Holdings Past Earnings Performance
Past criteria checks 0/6
Organigram Holdings's earnings have been declining at an average annual rate of -1797.1%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually. Revenues have been declining at an average rate of 0.6% per year.
Key information
-1,797.1%
Earnings growth rate
-1,698.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | -0.6% |
| Return on equity | -84.5% |
| Net Margin | -153.8% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Organigram Holdings Inc.'s (TSE:OGI) P/S Is On The Mark
Jun 09
OrganiGram Holdings Inc. (TSE:OGI) Analysts Are Reducing Their Forecasts For This Year
Apr 18What Did OrganiGram Holdings' (TSE:OGI) CEO Take Home Last Year?
Feb 12Analysts Are More Bearish On OrganiGram Holdings Inc. (TSE:OGI) Than They Used To Be
Jan 14Revenue & Expenses Breakdown
How Organigram Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 149 | -229 | 72 | 12 |
| 31 May 23 | 161 | -222 | 73 | 12 |
| 28 Feb 23 | 166 | -11 | 71 | 9 |
| 30 Nov 22 | 159 | -8 | 69 | 7 |
| 31 Aug 22 | 146 | -14 | 65 | 6 |
| 31 May 22 | 125 | -34 | 60 | 5 |
| 28 Feb 22 | 107 | -35 | 55 | 4 |
| 30 Nov 21 | 90 | -98 | 51 | 4 |
| 31 Aug 21 | 79 | -131 | 49 | 4 |
| 31 May 21 | 75 | -143 | 47 | 2 |
| 28 Feb 21 | 72 | -229 | 45 | 1 |
| 30 Nov 20 | 81 | -170 | 49 | 1 |
| 31 Aug 20 | 87 | -136 | 49 | 0 |
| 31 May 20 | 83 | -120 | 54 | 0 |
| 29 Feb 20 | 89 | -40 | 53 | 0 |
| 30 Nov 19 | 93 | -40 | 48 | 0 |
| 31 Aug 19 | 80 | -10 | 42 | 0 |
| 31 May 19 | 67 | 31 | 31 | 0 |
| 28 Feb 19 | 46 | 45 | 24 | 0 |
| 30 Nov 18 | 22 | 53 | 18 | 0 |
| 31 Aug 18 | 12 | 22 | 15 | 0 |
| 31 May 18 | 11 | 2 | 13 | 0 |
| 28 Feb 18 | 10 | -4 | 11 | 0 |
| 30 Nov 17 | 6 | -11 | 9 | 0 |
| 31 Aug 17 | 5 | -11 | 8 | 0 |
| 31 May 17 | 5 | -8 | 6 | 0 |
| 28 Feb 17 | 5 | -6 | 6 | 0 |
| 30 Nov 16 | 7 | 0 | 5 | 0 |
| 31 Aug 16 | 6 | 1 | 4 | 0 |
| 31 May 16 | 5 | 0 | 3 | 0 |
| 29 Feb 16 | 3 | 0 | 3 | 0 |
| 30 Nov 15 | 2 | -1 | 3 | 0 |
| 31 Aug 15 | 1 | -1 | 2 | 0 |
| 31 May 15 | 0 | -9 | 3 | 0 |
| 28 Feb 15 | 0 | -10 | 3 | 0 |
| 30 Nov 14 | 0 | -9 | 2 | 0 |
| 31 Aug 14 | 0 | -8 | 1 | 0 |
Quality Earnings: OGI is currently unprofitable.
Growing Profit Margin: OGI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if OGI's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare OGI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OGI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).
Return on Equity
High ROE: OGI has a negative Return on Equity (-84.48%), as it is currently unprofitable.